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Abstract
Introduction: Performing therapeutic plasma exchange (TPE) with albumin
replacement decreases coagulation factor and platelet levels. No defined guidelines
exist regarding laboratory testing to assess hemostasis in patients undergoing TPE.
Materials and methods: A survey to evaluate hemostasis testing with TPE was dis-
tributed using online survey software. One response per institution was analyzed
based on a hierarchical algorithm, excluding membrane filtration users, resulting in a
maximum of 120 respondents per question. Descriptive analysis was performed with
results reported as the number and/or frequency (%) of respondents to each question.
Results: The practices represented vary by institution type, number of apheresis
procedures per year, and performance of TPE on children. Prior to TPE planned
with albumin replacement, many respondents obtain laboratory studies for almost
all patients (54.9% outpatients and 68.7% inpatients); however, some do not rou-
tinely obtain laboratory studies (9.7% outpatients and 4.4% inpatients). Hemoglo-
bin/hematocrit, platelet count, fibrinogen, partial thromboplastin time (aPTT), and
international normalized ratio (INR) are obtained prior to all TPE by 62.5%,
53.4%, 31.0%, 18.1%, and 17.7% of respondents, respectively; however, 1.0%,
8.7%, 29.0%, 38.3%, and 35.4%, respectively, do not routinely obtain these studies.
Variation was observed in laboratory threshold values for action; the most common
reported were hemoglobin/hematocrit <7 g/dL or 21% (31.0%), platelet count
<50 × 109/L (24.1%), fibrinogen <100 mg/dL (65.3%), aPTT >reference range
and >1.5 times reference range (tied, 28.1%), and INR >1.5 (20.7%).
Conclusions: Practice variation exists in hemostasis laboratory testing and thresh-
old values for action with TPE. Further studies are needed to determine optimal
hemostasis testing strategies with TPE.
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1 | INTRODUCTION
Therapeutic plasma exchange (TPE) is a procedure in which
plasma is removed from a patient and replaced with an alter-
nate fluid, typically albumin or plasma. The primary intent
of the exchange is to remove pathogenic substances (eg,
toxins, autoantibodies, paraproteins) that have a role in the
pathophysiology of the disease in order to ameliorate disease
progression and provide clinical benefit to the patient. The
removal of the pathogenic substance is nonselective and
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physiologic (eg, immunoglobulins, complement, coagulation
factors) or therapeutic (eg, medications) substances, and
cells (eg, platelets) may also be removed. The unintended
removal of coagulation factors is especially critical when
replacement fluids other than donor plasma is used, and has
a potentially important hemostatic effect on patients under-
going invasive procedures immediately before or after TPE.
The removal of proteins involved in the coagulation cas-
cade has been extensively evaluated and is well
characterized.1–13 In addition, the platelet count may decrease
with TPE.2,4,5,9 Less is known about how to monitor TPE
associated coagulopathy and the risk of bleeding, especially
when there is ongoing anticoagulation and antiplatelet
therapy.1–3,14,15 A number of tests have been shown to be
reflective of this coagulopathy, including fibrinogen levels,
prothrombin time (PT), international normalized ratio (INR),
activated partial thromboplastin time (aPTT), and more
recently, rotational thromboelastometry (ROTEM).16,17 Fur-
thermore, there are currently no defined guidelines regarding
the frequency of testing, type of tests to perform, and action-
able thresholds for patients undergoing TPE treatment.
The aim of this study is to describe and characterize cur-
rent laboratory testing practices which are used to evaluate
the hemostatic capacity of patients undergoing TPE.
2 | MATERIALS AND METHODS
A survey to evaluate laboratory testing patterns associated
with performing TPE was developed by members of the
Coagulation Subcommittee of the American Society for
Apheresis (ASFA) Applications Committee. The survey
consisted of 37 questions, including demographic informa-
tion, questions regarding laboratory testing, case examples
to determine routine practice for TPE, and questions regard-
ing hemostasis management, particularly replacement fluid
choice (Supporting Information, 1). This article contains data
on the laboratory practices portion of the survey and the
hemostasis management practices are described in the asso-
ciated article by Zantek et al.18 The survey was beta tested
by members of the committee and additional members of
ASFA. More than 5000 email addresses in the ASFA distri-
bution lists received an email invitation to take the survey
which was administered through an online survey tool
(Survey Monkey). The initial survey invitation was sent on
February 12, 2016.
A total of 167 responses were received. Sixteen dupli-
cate responses were removed, retaining the response with
the most complete answers. When the institution was pro-
vided by the respondent, only one response per institution
was analyzed utilizing the following hierarchy: (1) Director
and one of the following—physician, residency/fellowship
program director, or member of physician teaching staff;
(2) Residency/fellowship program director; (3) Member of
physician teaching staff; (4) Physician; (5) Other when
listed as physician assistant or nurse practitioner; (6) Direc-
tor of apheresis; (7) Nurse; (8) Technician; and (9) Resi-
dent/Fellow, resulting in 24 additional responses removed
from analysis. One respondent entered multiple answers for
the question regarding position (physician, nurse, and
member of nonphysician teaching staff ) and regarding
physician specialty responded “I am not a physician.” This
respondent was included in the nurse category and not
included in the physician category in Table 1. Data from an
additional 5 respondents were excluded from analysis as
they indicated the method typically used for cell separation
was membrane filtration or centrifugation and membrane
filtration and these numbers are too small to analyze. This
resulted in a maximum of 122 potential respondents per
question; however, in the data presented here, the maxi-
mum number of responses per question was 120. The num-
ber of respondents to each question generally decreased
through the survey.
Descriptive statistical analysis was performed using
Excel 2010 (Microsoft Corporation, Redmond, WA).
Results are presented as the number and frequency (%) of
respondents for that particular question. Due to rounding,
the total percent may not equal 100%. Data analysis was
conducted by one author and reviewed by additional authors.
All authors had access to the data and contributed to aspects
of survey development, data analysis, writing the article,
and/or critical review and edit of the article.
3 | RESULTS
Demographic information of the survey respondents is pre-
sented in Table 1. In the analyzed data set, respondents were
primarily physicians (including physicians-in-training) and
nurses, in part due to the algorithm used to remove duplicate
responses from the same institution. While only 4 physicians
indicated their specialty was pediatrics, 68.1% (n = 81 of
119 respondents) performed TPE on children. In a follow-up
question, a pediatric procedure was predominately defined
by age rather than weight, with the most common threshold
for age being 18 years. A wide variety of thresholds were
used for weight, ranging from 5 to 50 kg.
Information regarding how the respondents routinely
perform TPE was obtained with a series of questions regard-
ing general management of a patient case which were asked
at the end of the data presented here. There was a gradual
decline in responses throughout the survey, such that only
112 participants responded to the question regarding plasma
separation method: 107 centrifugation, 5 membrane filtration
alone or with centrifugation, and 10 did not answer this
question. The 5 who indicated they use membrane filtration
were excluded from all analysis, as the numbers are too
small to analyze. The most common volume of TPE per-
formed (n = 106) would be 1.0 plasma volume (63.2%), fol-
lowed by 1.5 plasma volume (13.2%), 1.3 plasma volume
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TABLE 1 Demographic information of survey respondents and apheresis programs
Question (number of responders)a Number (%)b
Position at institutionb (n = 120)d
Physician (including physician in training-resident/fellow) 74 (61.7)
Director of apheresis service 27 (36.5)c
Member of physician teaching staff 22 (29.7)
Residency/fellowship program director 6 (8.1)
Other 6 (8.2)
Nurse 32 (26.7)
Director of apheresis service 2 (6.2)
Member of nonphysician teaching staff 2 (6.2)
Other 6 (19.4)
Director of apheresis (did not indicate physician or nurse) 10 (8.3)
Member of nonphysician teaching staff 1 (10.0)
Other 4 (3.3)
Type of institution (n = 120)
Academic medical center 81 (67.5)
Blood collection facility 16 (13.3)
Non-academic medical center 7 (5.8)
Contract provider of apheresis services 6 (5.0)
Outpatient facility that performs apheresis 1 (0.8)
Other 9 (7.5)
Number of beds for medical centers (n = 97)
>500 60 (61.9)
100–500 34 (35.0)
<100 3 (3.1)
Apheresis procedures per year (n = 117)
>700 47 (40.2)
500–700 18 (15.4)
100–500 41 (35.0)
<100 11 (9.4)
Departments which perform or oversee TPEb (n = 117)e
Pathology 41 (35.0)
Hematology 33 (28.2)
Nephrology 32 (27.4)
Blood collection facility 20 (17.1)
Neurology 15 (12.8)
Rheumatology 7 (6.0)
Medicine 6 (5.1)
Performed by outside source but overseen by pathology 7 (6.0)
Performed by outside source but overseen by neurology 3 (2.6)
Performed by outside source but overseen by hematology 2 (1.7)
Performed by outside source but overseen by nephrology 2 (1.7)
Performed by outside source but overseen by rheumatology 1 (0.8)
Performed by outside source but overseen by medicine 1 (0.8)
Other 22 (18.8)
Physician medical specialty (n = 104)
Pathology 45 (43.3)
Hematology 16 (15.4)
Nephrology 5 (4.8)
Pediatrics 4 (3.8)
Medicine 2 (1.9)
Other 10 (9.6)
I am not a physician 22 (21.1)
(Continues)
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(11.3%), 2.0 plasma volume (0.9%), with the remaining
respondents selecting other (11.3%). ACD-A would be used
for the anticoagulant during the procedure by more than 97%
of respondents.
Prior to and starting TPE procedures using replacement
fluid that does not contain plasma or cryoprecipitate labora-
tory studies are obtained at least rarely by 102 of
113 respondents for outpatients (90.3%) and 110 of
115 respondents for inpatients (95.7%) (Supporting Infor-
mation, 2). To determine if respondents obtain hemostasis
testing prior to TPE with planned albumin replacement
more often for inpatients versus outpatients, the individual
responses from each respondent for these two questions
were compared (Supporting Information, 3). Of the
113 respondents who answered both inpatient and outpa-
tient, 82 (72.6%) have the same practice for outpatients and
inpatients and 30 (26.5%) obtain testing more for
inpatients.
Respondents were next asked regarding which clinical
situations laboratory studies are obtained to assess a patient's
hemostatic function prior to TPE (n = 114) (Figure 1). Of
the 5 (4.4%) respondents who reported not routinely obtain-
ing laboratory studies, 3 indicated they do not obtain testing
for any of the conditions listed in Figure 1. In contrast, labo-
ratory studies are routinely obtained for all of the conditions
listed in Figure 1 by 11 (9.6%) respondents.
If the replacement fluid does not include plasma or cryo-
precipitate, respondents varied on what and when they
would obtain specific laboratory tests prior to and starting
TPE (Table 2). Only 1 respondent indicated they do not rou-
tinely obtain any of these 6 laboratory parameters and
6 respondents indicated they obtain all 6 laboratory parame-
ters prior to all procedures.
The laboratory threshold values at which the respondents
would change the procedure parameters or act upon also var-
ied (Table 3). While a fibrinogen level of <100 mg/dL was
the most common threshold reported (65.3%), 27.8% used a
higher threshold of <150 or < 200 mg/dL. The INR thresh-
old value was reported by the least number of respondents
(n = 58), but 53.4% (n = 31) reported they would use a
threshold of 1.5 or higher.
4 | DISCUSSION
TPE causes significant hemostatic changes in patients under-
going treatment. Use of replacement fluids without coagula-
tion factors (eg, 5% albumin) results in a decrease in
coagulation factors which may increase bleeding risk in sus-
ceptible patients.1–13 In addition, platelet count may decrease
with TPE.2,4,5,9 Treatment frequency and the degree of
exchange are other factors that can impact depletion of coag-
ulation factors involved in both primary and secondary
hemostasis. For example, in the absence of extravascular
redistribution of coagulation factors and significant synthe-
sis, ~60%-70% of plasma constituents is immediately
depleted with a 1.0 plasma volume exchange using 5% albu-
min and may be accompanied by a depletion of circulating
platelets.2,7,19 In particular, significant declines in procoagu-
lant coagulation factors such as factor V (FV), FVII, FVIII,
FIX, FX, and VWF activity occur.6,12,13 However, coagula-
tion factors are replenished at different rates. For example,
activities of FVIII, FIX, and VWF may return to normal
within 4 h after TPE, whereas other coagulation factors may
require 24 h or more to achieve pre-TPE activity
TABLE 1 (Continued)
Question (number of responders)a Number (%)b
Perform TPE procedures on children (n = 119)
Yes, adults and children 75 (63.0)
No 38 (31.9)
Yes, children only 6 (5.0)
a For some questions respondents were requested to check all that apply and the total number of responses is greater than the number of respondents.
b For questions that permitted more than 1 response, the percent is based on the number of respondents to the question.
c Subcategory percent is based on the number of main category responses.
d Total number of responses = 185.
e Total number of responses = 192.
FIGURE 1 Conditions for which laboratory studies are performed to
assess hemostasis prior to therapeutic plasma exchange (TPE). Respondents
were requested to select all conditions that apply. A total of 114 respondents
answered this question. Data represent the percentage of respondents that
would obtain testing for each condition
ZANTEK ET AL. 29
levels.1,6,10,13 One exception is fibrinogen, which achieves
66% of pre-apheresis levels by 72 h.5,12 Decreased coagula-
tion factors and other hemostatic elements such as platelets
do not necessarily equate with bleeding risk as adequate
hemostasis may occur with deficiency of these factors. In
addition, TPE also removes natural anticoagulants (eg, anti-
thrombin and protein C), so the risk of bleeding may not be
as high as predicted based on removal of procoagulant fac-
tors only.6,10,11,13 As a result, guidelines do not exist regard-
ing appropriate laboratory testing and thresholds for action
for patients undergoing TPE. Consistent with this lack of
guidelines is the wide variation in practice on when labora-
tory testing is obtained, what tests are obtained, and what are
important actionable thresholds. A survey on pediatric prac-
tice20 and a small survey on anticoagulation and apheresis21
also reported practice variation among centers. However, the
survey on pediatric practice did not survey coagulation
screening or monitoring practice.20
The impact of this wide variation in practice on clinical
outcomes is largely unknown. For illustrative purposes con-
sider testing for fibrinogen. A fibrinogen threshold of
<100 mg/dL was the most common threshold reported
(as indicated by 65.3% of respondents), but it is unknown if
a different threshold would better balance the risk of bleed-
ing and potential use of replacement fluids containing coagu-
lation factors (eg, plasma and cryoprecipitate). The optimal
frequency for laboratory testing is unknown and is likely
based on institutional or physician practice, which may not
be evidenced based. Testing prior to every procedure (per-
formed by 31.0% of respondents) may result in many
patients getting unnecessary testing, but not routinely obtain-
ing testing (as is done by 29.0% of respondents) may result
in a patient undergoing TPE with a replacement fluid with-
out coagulation factors in the setting of already marked
hypofibrinogenemia.
Furthermore, in patients undergoing TPE, bleeding/
hematoma rates are low, ranging from 0.26% to 2.46%.22,23
Laboratory studies such as the INR, aPTT, and platelet count
have been found to be poor predictors of bleeding risk.24,25
Thus, testing with these common coagulation tests may not
readily identify who is at greatest risk for bleeding.
Inappropriate over test utilization may have a negative
impact on the patient.26–29 Potential negatives include a
TABLE 2 Laboratory testing routinely performed prior to therapeutic plasma exchange (TPE), if the replacement fluid does not include plasma or
cryoprecipitate
Fibrinogen
(n = 100) (%)
PTa
(n = 94) (%)
INRa
(n = 96) (%)
aPTTa
(n = 94) (%)
Hemoglobin or
hematocrit
(n = 104) (%)
Platelet count
(n = 103) (%)
Not routinely obtained 29.0 37.2 35.4 38.3 1.0 8.7
Obtained only prior to the first procedure 2.0 13.8 12.5 10.6 8.6 9.7
Obtained prior to some but not all procedures 38.0 31.9 34.4 33.0 27.9 28.2
Obtained prior to all procedures 31.0 17.0 17.7 18.1 62.5 53.4
a Abbreviations: aPTT = activated partial thromboplastin time; INR = international normalized ratio; PT = prothrombin time.
TABLE 3 Laboratory threshold values used to change the procedure or
act upon
Parameter Threshold value %
Fibrinogen <Reference range 1.4
(n = 72) <50 mg/dL 2.8
<100 mg/dL 65.3
<150 mg/dL 20.8
<200 6.9
Other 2.8
INRa >Reference range 20.7
(n = 58) >1.25 10.3
>1.5 20.7
>1.75 6.9
>2.0 17.2
>2.5 1.7
>3.0 5.2
>4.0 1.7
Other 15.5
aPTTa >Reference range 28.1
(n = 57) >1.25 times the reference range 8.8
>1.5 times the reference range 28.1
>1.75 times the reference range 5.3
>2.0 times the reference range 12.3
Other 17.5
Hemoglobin or hematocrit <Reference range 3.6
(n = 84) <6 g/dL or 18% 7.1
<7 g/dL or 21% 31.0
<8 g/dL or 24% 20.2
<9 g/dL or 27% 8.3
Threshold determined based on the
patients hemoglobin and blood
volume relative to the volume of
the extracorporeal circuit
26.2
Other 3.6
Platelet count <Reference range 7.2
(n = 83) <10 × 109/L 9.6
<20 × 109/L 20.5
<50 × 109/L 24.1
<100 × 109/L 9.6
<150 × 109/L 3.6
Other 25.3
a PTT = activated partial thromboplastin time; INR = international normalized
ratio.
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small risk of injury and infection with phlebotomy or acces-
sing central venous catheters or fistulas, iatrogenic blood
loss due to phlebotomy, false-positive or -negative results or
spurious results due to a number of pre- and postanalytical
factors (eg, heparin contamination from central lines causing
a falsely elevated aPTT), test misinterpretation by providers
to a indicate a higher or lower risk for bleeding risk, and
higher costs.30–33
Due to lack of published studies on laboratory testing and
TPE and the subjective nature of our study design, future
studies need to be conducted to determine the best laboratory
testing practice for improved clinical outcomes and cost effec-
tiveness. Clinical history and patient factors should be consid-
ered when determining if, what, and when to perform
laboratory testing. It would be reasonable to obtain a basic
laboratory evaluation of hemostasis (such as hemoglobin/
hematocrit, platelet count, PT/INR, PTT, and fibrinogen) for
most patients prior to the initial TPE in a series. More exten-
sive evaluations or ongoing testing should be based on the
patient's medical history and potential hemorrhage or throm-
bosis risk, if the results would change management. This
action is also supported by the ASFA Choosing Wisely rec-
ommendations, part the Choosing Wisely initiative of the
ABIM Foundation, which states “Do not routinely monitor
coagulation tests during a course of therapeutic plasma
exchange, unless the procedure is performed daily.”34
Additional studies are needed to establish the clinically
appropriate laboratory action thresholds. These thresholds
should not be based exclusively on the laboratory reference
range. For example, many respondents use action levels well
outside of the laboratory reference interval (eg, 68.1% of
respondents used a fibrinogen of <100 mg/dL or lower
which is well below typical fibrinogen reference range limits
of 150-200 mg/dL).
This study has several limitations. The survey respon-
dents were largely from U.S. centers so it is unclear if the
survey results can be generalized to non-U.S. apheresis prac-
tice. Participant response progressively decreased during the
survey likely due to survey fatigue and the large number of
questions being asked. In addition, five centers reported
using membrane filtration and were excluded from analysis
and 15 respondents dropped out of the survey prior to this
question so their method of plasma separation is unknown.
Furthermore, we did not inquire about other tests of hemo-
stasis such as thromboelastography (TEG) and rotational
elastometry (ROTEM).17,35 However, based on the authors'
experiences, the use of TEG and ROTEM was considered
not to be a test routinely utilized during TPE treatment and
therefore was not queried.
5 | CONCLUSION
This survey demonstrates wide variation in hemostasis test-
ing practice in the setting of TPE. These descriptive data do
not establish what should be the best practice, but identify
areas of equipoise. Future studies need to be conducted to
determine the best laboratory testing practice for improved
clinical outcomes and cost effectiveness.
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